Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Asthma COPD Drugs Market

ID: MRFR/HC/47725-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Asthma COPD Drugs Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 China Asthma COPD Drugs Market, BY Drug Type (USD Billion)
      1. 4.1.1 Bronchodilators
      2. 4.1.2 Corticosteroids
      3. 4.1.3 Combination Therapy
      4. 4.1.4 Leukotriene Modifiers
      5. 4.1.5 Monoclonal Antibodies
    2. 4.2 China Asthma COPD Drugs Market, BY Route of Administration (USD Billion)
      1. 4.2.1 Inhalation
      2. 4.2.2 Oral
      3. 4.2.3 Injectable
      4. 4.2.4 Nasal
      5. 4.2.5 Transdermal
    3. 4.3 China Asthma COPD Drugs Market, BY Patient Demographics (USD Billion)
      1. 4.3.1 Children
      2. 4.3.2 Adults
      3. 4.3.3 Elderly
      4. 4.3.4 Pregnant Women
      5. 4.3.5 Patients with Comorbidities
    4. 4.4 China Asthma COPD Drugs Market, BY Therapeutic Area (USD Billion)
      1. 4.4.1 Asthma
      2. 4.4.2 Chronic Obstructive Pulmonary Disease
      3. 4.4.3 Allergic Rhinitis
      4. 4.4.4 Respiratory Infections
      5. 4.4.5 Pulmonary Hypertension
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the China Asthma COPD Drugs Market
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the China Asthma COPD Drugs Market
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AstraZeneca (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 GSK (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Boehringer Ingelheim (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Teva Pharmaceutical Industries (IL)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pfizer (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY DRUG TYPE
    3. 6.3 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    4. 6.4 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    5. 6.5 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
    6. 6.6 KEY BUYING CRITERIA OF CHINA ASTHMA COPD DRUGS MARKET
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHINA ASTHMA COPD DRUGS MARKET
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHINA ASTHMA COPD DRUGS MARKET
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHINA ASTHMA COPD DRUGS MARKET
    11. 6.11 SUPPLY / VALUE CHAIN: CHINA ASTHMA COPD DRUGS MARKET
    12. 6.12 CHINA ASTHMA COPD DRUGS MARKET, BY DRUG TYPE, 2024 (% SHARE)
    13. 6.13 CHINA ASTHMA COPD DRUGS MARKET, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 CHINA ASTHMA COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    15. 6.15 CHINA ASTHMA COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    16. 6.16 CHINA ASTHMA COPD DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    17. 6.17 CHINA ASTHMA COPD DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    18. 6.18 CHINA ASTHMA COPD DRUGS MARKET, BY THERAPEUTIC AREA, 2024 (% SHARE)
    19. 6.19 CHINA ASTHMA COPD DRUGS MARKET, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG TYPE, 2026-2035 (USD Billion)
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
      4. 7.2.4 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Asthma COPD Drugs Market Segmentation

China Asthma COPD Drugs Market By Drug Type (USD Billion, 2022-2035)

  • Bronchodilators
  • Corticosteroids
  • Combination Therapy
  • Leukotriene Modifiers
  • Monoclonal Antibodies

China Asthma COPD Drugs Market By Route of Administration (USD Billion, 2022-2035)

  • Inhalation
  • Oral
  • Injectable
  • Nasal
  • Transdermal

China Asthma COPD Drugs Market By Patient Demographics (USD Billion, 2022-2035)

  • Children
  • Adults
  • Elderly
  • Pregnant Women
  • Patients with Comorbidities

China Asthma COPD Drugs Market By Therapeutic Area (USD Billion, 2022-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Rhinitis
  • Respiratory Infections
  • Pulmonary Hypertension

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓